<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MERCAPTOPURINE (6-MP, 6-MERCAPTOPURINE) <img border="0" src="../images/pr.gif"/></span><br/>(mer-kap-toe-pyoor'een)<br/><span class="topboxtradename">Purinethol<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite, purine antagonist</span>; <span class="classification">immunosuppressant</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antimetabolite and purine antagonist. Inhibits purine metabolism by unclear mechanism. Blocks conversion of inosinic acid
         to adenine and xanthine ribotides within sensitive tumor cells. Also inhibits adenine-containing coenzymes, suggesting an
         influence over multiple cellular reactions.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Delayed immunosuppressive properties and carcinogenic potential.</p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily for acute lymphocytic and myelogenous leukemia. Response in adults is less than in children, but mercaptopurine
         is initial drug of choice. In chronic granulocytic leukemia, produces temporary remission.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prevention of transplant graft rejection; SLE; rheumatoid arthritis; Crohn's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prior resistance to mercaptopurine; first trimester of pregnancy (category D); lactation; infections.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; concomitant use with allopurinol.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Leukemias</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO Loading Dose</span> 2.5 mg/kg/d, may increase up to 5 mg/kg/d after 4 wk if needed <span class="rdroute">PO Maintenance Dose</span> 1.252.5 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give total daily dose at one time.</li>
<li>Reduce dose of mercaptopurine usually by <small>1/3</small><small>1/4</small> when given concurrently with allopurinol.</li>
<li>Store tablets in light- and air-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Stomatitis, esophagitis, anorexia, nausea, vomiting, diarrhea, intestinal ulcerations, impaired liver function, <span class="speceff-life">hepatic necrosis</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Leukopenia</span>, anemia, eosinophilia, pancytopenia, <span class="speceff-life">thrombocytopenia</span>, abnormal bleeding, bone marrow hypoplasia. <span class="typehead">Urogenital:</span> Hyperuricemia, oliguria, renal impairment. <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Drug fever. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Allopurinol</b> may inhibit metabolism and thus increase toxicity of mercaptopurine; may potentiate or antagonize anticoagulant effects of
      <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 50% absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Distributes into total body water. <span class="typehead">Metabolism:</span> Rapidly metabolized by xanthine oxidase in liver. <span class="typehead">Elimination:</span> 11% excreted in urine within 6 h. <span class="typehead">Half-Life:</span> 2050 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC with differential, platelet count, Hgb, Hct, and liver functions closely.</li>
<li>Monitor for S&amp;S of liver damage. Hepatic toxicity occurs most often when dose exceeds 2.5 mg/kg/d. Jaundice signals onset
            of hepatic toxicity and may necessitate terminating use.
         </li>
<li>Withhold drug and notify physician at the first sign of an abnormally large or rapid fall in platelet and leukocyte counts.</li>
<li>Record baseline data related to I&amp;O ratio and pattern and body weight.</li>
<li>Check vital signs daily. Report febrile states promptly.</li>
<li>Protect patient from exposure to trauma, infections, or other stresses (restrict visitors and personnel who have colds) during
            periods of leukopenia.
         </li>
<li>Report nausea, vomiting, or diarrhea. These may signal excessive dosage, especially in adults.</li>
<li>Watch for signs of abnormal bleeding (ecchymoses, petechiae, melena, bleeding gums) if thrombocytopenia develops; report immediately.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any signs of bleeding (e.g., hematuria, bruising, bleeding gums).</li>
<li>Report signs of hepatic toxicity (see Appendix F).</li>
<li>Increase hydration (1012 glasses of fluid daily) to reduce risk of hyperuricemia. Consult physician about desirable
            volume.
         </li>
<li>Notify physician of onset of chills, nausea, vomiting, flank or joint pain, swelling of legs or feet, or symptoms of anemia.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>